Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04981509
Title Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

renal cell carcinoma

papillary renal cell carcinoma


Atezolizumab + Bevacizumab + Erlotinib

Age Groups: adult | senior | child
Covered Countries USA

No variant requirements are available.